BREACH OF SKIN BARRIER AS A LEADING FACTOR IN THE FORMATION OF LOCAL INFLAMMATORY PROCESS IN ATOPIC DERMATITIS.

Cover Page

Abstract


Atopic dermatitis (also known as infantile eczema, atopic eczema) is a chronic inflammatory skin disease, accompanied by intense itching and continuously relapsing eczematous lesions. Despite the fact that the disease most often begins in early childhood, it is also quite widespread among adults. The disease is often accompanied by a fairly severe psychoemotional stress in both patients and their families, increases the risk of seasonal allergic rhinitis and asthma. Pathogenesis of atopic dermatitis is based on an imbalance in the proliferation of T lymphocytes towards the proliferation of Type 2 T helper cells with a high IgE response to allergens penetrating into the deep layers of the skin. A significant role is attributed to the colonization of the affected skin with Staphylococcus aureus. At present time, the disease is deemed to be an incurable condition, in which the failure of the epidermal barrier is considered to be the leading cause of onset of the disease. Prevention of breaches of the skin barrier, treatment of exacerbations of immuno-mediated inflammation of the skin with corticosteroids along with calcineurin inhibitors in the second line of therapy, as well as control of Staphylococcus skin infections retain their relevance.

About the authors

A. V. Kudryavtseva

I. M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: kudassia@gmail.com

Russian Federation Trubetskaya str., 8, bldg 2, Moscow, 119991, Russia

References

  1. Flavia Alvim, Valeria Aoki. Skin barrier in atopic dermatitis. An Bras Dermatol 2010; 85 (2): 184—194.
  2. Cristopher E., Kligman A. M. Visualization of the celllayers of the stratum corneum. J Invest Dermatol 1964; 42: 406—407.
  3. Blank I. H., Cutaneous barriers. J Invest Dermatol. 1965; 45: 249—256.
  4. Scheuplein R. J., Blank I. H. Permeability of he skin. Physiol Rev 1971; 51: 702—747.
  5. Sato J., Denda M., Chang S., Elias P. M., Feingold K. R. Abrupt decreases in environmental humidity induce abnormalities in permeability barrier homeostasis. J Invest Dermatol 2002; 119: 900—904.
  6. Odland G., Reed T. Epidermis. In: Zelickson A., ed. Ultrastructure of normal and abnormal skin. Philadelphia: Lea & Fabiger; 1967: 54—75.
  7. Michaels A. S., Chandrasekaran S. K., Shaw J. E. Drug permeation through human skin: theory and in vitro experimental measurement. Am Inst Chem Eng J 1975; 21: 985— 996.
  8. Johnson M. E., Blankschtein D., Langer R. Evaluation of solute permeation through the stratum corneum: lateral bilayer diffusion as the primary transport mechanism. J Pharm Sci 1997; 86: 1162—1172.
  9. Weidinger S., Novak N. Atopic dermatitis. Lancet. 2016 Mar 12; 387 (10023): 1109—1122. Литература
  10. Kurchenko A. I. Sravnitel'naya harakteristika immunogistohimicheskoj kartiny ochagov porazhenij kozhi u bol'nyh s IgE-zavisimoj i IgEnezavisimoj formami atopicheskogo dermatita. Ukrainskij medicinskij zhurnal 2006; 1 (51): 114 —117. [Курченко А. И. Сравнительная характеристика иммуногистохимической картины очагов поражений кожи у больных с IgE-зависимой и IgE-независимой формами атопического дерматита.Украинский ме- дицинский журнал 2006; 1 (51): 114 —117.]
  11. Cho S. H., Strickland I., Tomkinson A. еt. al. Preferential bin ding of Staphylococcus aureus to skin sites of Th2 mediated inflammation in a murine model. J Invest Dermatol 2001; 116: 658—663.
  12. Wollina U. Microbiome in atopic dermatitis. Clin Cosmet Investig Dermatol 2017 Feb 22; 10: 51—56.
  13. Wang B., McHugh B. J., Qureshi A., Campopiano D. J., Clarke D. J., Fitzgerald J. R., Dorin J. R., Weller R., Davidson D. J. IL-1EInduced Protection of Keratinocytes against Staphylococcus aureus-Secreted Proteases Is Mediated by Human E-Defensin 2. J Invest Dermatol 2017 Jan; 137 (1): 95—105.
  14. Dinges M. M., Orwin P. M., Schlievert P. M. Exotoxins of Staphylococcus aureus.Clin. Microbiol Rev 2000; 13 (1): 16—34.
  15. Breuer K., Wittmann M., Bosche B. et al. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy 2000; 55: 551—555.
  16. Schlievert P. M., Case L. C., Strandberg K. L. et al. Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. Clin. Infect. Dis 2008; 46: 1562—1567.
  17. Ong P. Y., Leung D. Y. Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review. Clin Rev Allergy Immunol 2016 Dec; 51 (3): 329—337.
  18. Nakatsuji T., Chen T. H., Narala S., Chun K. A., Two A. M., Yun T., Shafiq F. et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med 2017 Feb 22; 9 (378). pii: eaah4680. doi:10.1126/ scitranslmed.aah4680.
  19. Kudryavceva A. V., Savvina YU. A., Morozova O. A. Vydelenie razlichnyh vidov stafilokokka s porazhennoj kozhi u detej i podrostkov s atopicheskim dermatitom. Ross allergol zhurn 2015; (3): 41—46. [Кудрявцева А. В., Савви- на Ю. А., Морозова О. А. Выделение различ- ных видов стафилококка с пораженной кожи у детей и подростков с атопическим дерматитом. Росс аллергол журн 2015; (3): 41—46.]
  20. Kudryavceva A. V., Katosova L. K., Balabolkin I. P., Aseeva V. G. Rol' zolotistogo stafilokokka pri atopicheskom dermatite u detej. Pediatriya. ZHurnal im. G. N. Speranskogo 2003; 82 (6): 32—36. [Кудрявцева А. В., Катосова Л. К., Балаболкин И. П., Асеева В. Г. Роль золотистого стафилококка при атопическом дерматите у детей. Педиатрия. Журнал им. Г. Н. Сперанского 2003; 82 (6): 32—36.]
  21. Kudryavceva A. V., Fluer F. S., Balabolkin I. I., Prohorov V. YA., Katosova L. K., Lazareva A. V., Ponomarenko O. A. Zavisimost' tyazhesti techeniya atopicheskogo dermatita u detej ot toksinproduciruyushchih svojstv shtammov zolotistogo stafilokokka. Ross pediatr zhurn 2009; 3: 31—35. [Кудрявцева А. В., Флуер Ф. С., Балаболкин И. И., Прохоров В. Я., Катосова Л. К., Лазарева А. В., Пономаренко О. А. Зависимость тяжести течения атопического дерматита у детей от токсинпродуцирующих свойств штаммов золотистого стафилококка. Росс педиатр журн 2009; (3): 31—35.]
  22. Kudryavtseva A., Savvina J., Nescorodova K., Morozova O. Staphylococci and acute / chronic form of atopic dermatitis in children. Allergy 2016; 71 (102): 118.
  23. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. Boyce J.A., Assa'ad A., Burks A.W., Jones S.M., Sampson H.A., Wood R.A., Plaut M., Cooper S.F. et al.J Allergy Clin Immunol 2010 Dec; 126 (6): 1105—1118.
  24. Ebisawa M. Menegement of food allergy in Japan, 2008. Allergology International 2009; 58: 475—483.
  25. Blume-Peytavi U., Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 2011 May; 25 (5): 508—515.
  26. Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017 Mar 4. doi: 10.1111/ijd.13485.
  27. Korotkij N. G., Taganov A. V., Tihomirov A. A. Rezul'taty mnogocentrovogo nesravnitel'nogo issledovaniya ehffektivnosti chetyrekh lekarstvennyh form advantana u detej s atopicheskim dermatitom. Vestn dermatol i venerol 2002; 1: 43—46. [Короткий Н. Г., Таганов А. В., Тихо- миров А. А. Результаты многоцентрового несравнительного исследования эффективности четырех лекарственных форм адвантана у детей с атопическим дерматитом. Вестн дерматол и венерол 2002; (1): 43—46.]
  28. Lyan N. A., Smolkin YU. S. Metilprednizolona aceponat (Advantan) — ser'eznyı˘ shag k progressu v lechenii atopicheskogo dermatita u deteı˘ . Allergologiya, immunologiya v pediatrii 2007; 2 (11): 17—21. [Лян Н. А., Смол- кин Ю. С. Метилпреднизолона ацепонат (Адвантан) — серьезный шаг к прогрессу в лечении атопического дерматита у детей. Аллергология, иммунология в педиатрии 2007; 2 (11): 17—21.]
  29. Bieber T., Vick K., Fölster-Holst R., BelloniFortina A., Städtler G., Worm M., Arcangeli F. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007 Feb; 62 (2): 184—189.
  30. Hamaganova I. V. Advantan v lechenii kon taktnyh allergicheskih dermatitov, obuslovlennyh primeneniem dekorativnoj kosmetiki. Vestn dermatol venerol 2000; 5: 58—59. [Хамага- нова И. В. Адвантан в лечении контактных аллергических дерматитов, обусловленных применением декоративной косметики. Вестн дерматол венерол 2000; (5): 58—59.]
  31. Lin Y. T., Wang C. T., Chiang B. L. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol 2007 Dec; 33 (3): 167—77.
  32. Consensus Conference on Clinical Management of pediatric Atopic Dermatitis. Elena Galli, Iria Neri, Giampaolo Ricci et al. Ital J Pediatr. 2016;42:26p
  33. Sajic D., Asiniwasis R., Skotnicki-Grant S. A look at epidermal barrier function in atopic dermatitis: physiologic lipid replacement and the role of ceramides. Skin Therapy Lett 2012; 17 (7): 6—9.
  34. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. Eichenfield L. F., Tom W. L., Berger T. G., Krol A., Paller A. S., Schwarzenberger K., Bergman J. N., et al. J Am Acad Dermatol 2014 Jul; 71 (1):116—132.
  35. Balabolkin I. I., Grebenyuk V. N. Atopicheskij dermatit u detej. M.: Medicina, 1999, 238. [Балаболкин И. И., Гребенюк В. Н. Атопический дерматит у детей. М.: Медицина, 1999, 238.]

Statistics

Views

Abstract - 323

PDF (Russian) - 266

PlumX

Dimensions


Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies